Acumen Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $151.9M
- Price
- $2.10
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.45%
- Volume
- 623.1K
About
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Quick stats
Shares outstanding72.3M
Computed float37.4M
Float / shares51.7%
Cash runway (months)12.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001576885
Websitehttps://acumenpharm.com
AI Summary
AI-generated1/21
minorneutralother
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
Acumen Pharmaceuticals (NASDAQ: ABOS) will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET, with registration required in advance and a webcast archived for at least one year.
Acumen is a clinical-stage biopharmaceutical company developing therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer's disease; its lead candidate is sabirnetug (ACU193), currently in the Phase 2 ALTITUDE-AD trial in early symptomatic patients.
The release contains no new clinical or financial data, but the investor day is a likely venue for pipeline updates on sabirnetug and its subcutaneous formulation and JCR collaboration programs.